Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Spinocerebellar Degenerations 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Colorectal Neoplasms 1

Interventions

pembrolizumab 124Cisplatin 27lenvatinib 24Carboplatin 24Paclitaxel 19Docetaxel 16Fluorouracil 13Capecitabine 11Pemetrexed 10Gemcitabine 10Saline Solution 8Oxaliplatin 8epacadostat 6Leucovorin 5Irinotecan 5Cetuximab 5olaparib 4Bevacizumab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3enzalutamide 3durvalumab 3Nivolumab 3Etoposide 3trametinib 2etoposide phosphate 2dabrafenib 2Tretinoin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × vicriviroc × Clear all
NCT03631407 2024-11-21

MK-7690-046

Merck Sharp & Dohme LLC

Phase 2 Completed
41 enrolled 20 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡